https://drugnews.com.tw/2026-07-081.0 https://drugnews.com.tw/articles/2026-07-080.9 https://drugnews.com.tw/en/2026-07-080.85 https://drugnews.com.tw/en/articles/2026-07-080.75 https://drugnews.com.tw/en/about.html2026-07-080.65 https://drugnews.com.tw/en/guides/2026-07-080.7 https://drugnews.com.tw/en/guides/clinical-endpoints.html2026-07-080.7 https://drugnews.com.tw/en/guides/regulatory-milestones.html2026-07-080.7 https://drugnews.com.tw/en/guides/biotech-valuation.html2026-07-080.7 https://drugnews.com.tw/en/guides/bd-licensing-terms.html2026-07-080.7 https://drugnews.com.tw/en/guides/safety-cmc-risk.html2026-07-080.7 https://drugnews.com.tw/en/guides/market-sizing.html2026-07-080.7 https://drugnews.com.tw/en/guides/patent-competition.html2026-07-080.7 https://drugnews.com.tw/en/guides/cash-runway.html2026-07-080.7 https://drugnews.com.tw/en/services.html2026-07-080.65 https://drugnews.com.tw/en/subscribe.html2026-07-080.65 https://drugnews.com.tw/en/team.html2026-07-080.65 https://drugnews.com.tw/topics/2026-07-080.85 https://drugnews.com.tw/topics/biotech-investing.html2026-07-080.75 https://drugnews.com.tw/topics/biotech-valuation.html2026-07-080.75 https://drugnews.com.tw/topics/bd-licensing.html2026-07-080.75 https://drugnews.com.tw/topics/clinical-data.html2026-07-080.75 https://drugnews.com.tw/topics/cmc.html2026-07-080.75 https://drugnews.com.tw/topics/drug-development.html2026-07-080.75 https://drugnews.com.tw/topics/big-pharma.html2026-07-080.75 https://drugnews.com.tw/topics/glp1.html2026-07-080.75 https://drugnews.com.tw/market-radar.html2026-07-080.85 https://drugnews.com.tw/market-radar.json2026-07-080.5 https://drugnews.com.tw/brand-profile.json2026-07-080.5 https://drugnews.com.tw/companies.html2026-07-080.75 https://drugnews.com.tw/about.html2026-07-080.75 https://drugnews.com.tw/guides/0.8 https://drugnews.com.tw/guides/clinical-endpoints.html0.7 https://drugnews.com.tw/guides/regulatory-milestones.html0.7 https://drugnews.com.tw/guides/biotech-valuation.html0.7 https://drugnews.com.tw/guides/bd-licensing-terms.html0.7 https://drugnews.com.tw/guides/safety-cmc-risk.html0.7 https://drugnews.com.tw/guides/market-sizing.html0.7 https://drugnews.com.tw/guides/patent-competition.html0.7 https://drugnews.com.tw/guides/cash-runway.html0.7 https://drugnews.com.tw/subscribe.html0.8 https://drugnews.com.tw/services.html0.8 https://drugnews.com.tw/team.html0.7 https://drugnews.com.tw/llms.txt2026-07-080.5 https://drugnews.com.tw/ai-index.json2026-07-080.5 https://drugnews.com.tw/search-intents.json2026-07-080.5 https://drugnews.com.tw/feed.json2026-07-080.5 https://drugnews.com.tw/knowledge-graph.json2026-07-080.5 https://drugnews.com.tw/opensearch.xml0.4 https://drugnews.com.tw/articles/type/free.html2026-07-080.7 https://drugnews.com.tw/articles/type/paid.html2026-06-260.7 https://drugnews.com.tw/articles/category/business-analysis.html2026-07-080.6 https://drugnews.com.tw/articles/category/fundamental-analysis.html2026-06-160.6 https://drugnews.com.tw/articles/category/medical-conference.html2026-06-160.6 https://drugnews.com.tw/articles/category/paid-deep-analysis.html2026-06-260.6 https://drugnews.com.tw/articles/category/big-pharma.html2025-09-170.6 https://drugnews.com.tw/articles/archive/2026-07.html2026-07-080.7 https://drugnews.com.tw/articles/archive/2026-06.html2026-06-300.7 https://drugnews.com.tw/articles/archive/2026-05.html2026-05-310.7 https://drugnews.com.tw/articles/archive/2026-04.html2026-04-300.7 https://drugnews.com.tw/articles/archive/2025-09.html2025-09-170.7 https://drugnews.com.tw/articles/archive/2025-08.html2025-08-310.7 https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html2026-07-080.8 https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html2026-07-080.8 https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html2026-07-070.8 https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html2026-07-070.8 https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html2026-07-060.8 https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html2026-07-060.8 https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html2026-07-050.8 https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html2026-07-050.8 https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html2026-07-040.8 https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials.html2026-07-040.8 https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html2026-07-030.8 https://drugnews.com.tw/articles/2026-07-03-revmed-biotech.html2026-07-030.8 https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html2026-07-020.8 https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp.html2026-07-020.8 https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html2026-07-010.8 https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b.html2026-07-010.8 https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html2026-06-300.8 https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback.html2026-06-300.8 https://drugnews.com.tw/articles/2026-06-29-biotech-ipo-en.html2026-06-290.8 https://drugnews.com.tw/articles/2026-06-29-biotech-ipo.html2026-06-290.8 https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html2026-06-280.8 https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound.html2026-06-280.8 https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html2026-06-270.8 https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html2026-06-270.8 https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html2026-06-260.8 https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism.html2026-06-260.8 https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform-en.html2026-06-250.8 https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform.html2026-06-250.8 https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html2026-06-240.8 https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu.html2026-06-240.8 https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html2026-06-220.8 https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition.html2026-06-220.8 https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html2026-06-210.8 https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda.html2026-06-210.8 https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury-en.html2026-06-200.8 https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury.html2026-06-200.8 https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en.html2026-06-190.8 https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis.html2026-06-190.8 https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy.html2026-06-170.8 https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html2026-06-170.8 https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html2026-06-160.8 https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine.html2026-06-160.8 https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html2026-06-150.8 https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t.html2026-06-150.8 https://drugnews.com.tw/articles/2026-06-14-revolution-medicines-en.html2026-06-140.8 https://drugnews.com.tw/articles/2026-06-14-revolution-medicines.html2026-06-140.8 https://drugnews.com.tw/articles/2026-06-13-anhorn-ai-drug-development-en.html2026-06-130.8 https://drugnews.com.tw/articles/2026-06-13-dcard-261654701.html2026-06-130.8 https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html2026-06-120.8 https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612.html2026-06-120.8 https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle-en.html2026-06-110.8 https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle.html2026-06-110.8 https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.html2026-06-100.8 https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer.html2026-06-100.8 https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story-en.html2026-06-100.8 https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story.html2026-06-100.8 https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition-en.html2026-06-090.8 https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition.html2026-06-090.8 https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.html2026-06-080.8 https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era.html2026-06-080.8 https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future-en.html2026-06-070.8 https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future.html2026-06-070.8 https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy-en.html2026-06-060.8 https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy.html2026-06-060.8 https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery-en.html2026-06-050.8 https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery.html2026-06-050.8 https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss-en.html2026-06-040.8 https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss.html2026-06-040.8 https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing-en.html2026-06-030.8 https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing.html2026-06-030.8 https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy-en.html2026-06-020.8 https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy.html2026-06-020.8 https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth-en.html2026-06-010.8 https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth.html2026-06-010.8 https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis-en.html2026-05-310.8 https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis.html2026-05-310.8 https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling-en.html2026-05-300.8 https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling.html2026-05-300.8 https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions-en.html2026-05-290.8 https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions.html2026-05-290.8 https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system-en.html2026-05-280.8 https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system.html2026-05-280.8 https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework-en.html2026-05-270.8 https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety-en.html2026-05-270.8 https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework.html2026-05-270.8 https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety.html2026-05-270.8 https://drugnews.com.tw/articles/2026-05-26-weight-loss-side-effect-new-track-en.html2026-05-260.8 https://drugnews.com.tw/articles/2026-05-26-weight-loss-side-effect-new-track.html2026-05-260.8 https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets-en.html2026-05-250.8 https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets.html2026-05-250.8 https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity-en.html2026-05-240.8 https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity.html2026-05-240.8 https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend-en.html2026-05-230.8 https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend.html2026-05-230.8 https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow-en.html2026-05-220.8 https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow.html2026-05-220.8 https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect-en.html2026-05-210.8 https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect.html2026-05-210.8 https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding-en.html2026-05-200.8 https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding.html2026-05-200.8 https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth-en.html2026-05-190.8 https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth.html2026-05-190.8 https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake-en.html2026-05-180.8 https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake.html2026-05-180.8 https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge.html2026-05-170.8 https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge-en.html2026-05-170.8 https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson-en.html2026-05-170.8 https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson.html2026-05-170.8 https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk-en.html2026-05-160.8 https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk.html2026-05-160.8 https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline-en.html2026-05-150.8 https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline.html2026-05-150.8 https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation-en.html2026-05-140.8 https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation.html2026-05-140.8 https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback-en.html2026-05-130.8 https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback.html2026-05-130.8 https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition-en.html2026-05-120.8 https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition.html2026-05-120.8 https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy.html2026-05-110.8 https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy-en.html2026-05-110.8 https://drugnews.com.tw/articles/2026-05-10-glp1-medicare-policy-delay-en.html2026-05-100.8 https://drugnews.com.tw/articles/2026-05-10-glp1-medicare-policy-delay.html2026-05-100.8 https://drugnews.com.tw/articles/2026-05-09-clinical-trial-fraud-fda-withdrawal-en.html2026-05-090.8 https://drugnews.com.tw/articles/2026-05-09-clinical-trial-fraud-fda-withdrawal.html2026-05-090.8 https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth-en.html2026-05-080.8 https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth.html2026-05-080.8 https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war-en.html2026-05-070.8 https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war.html2026-05-070.8 https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop-en.html2026-05-060.8 https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop.html2026-05-060.8 https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction-en.html2026-05-050.8 https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction.html2026-05-050.8 https://drugnews.com.tw/articles/2026-05-04-hair-growth-drug-breakthrough-en.html2026-05-040.8 https://drugnews.com.tw/articles/2026-05-04-hair-growth-drug-breakthrough.html2026-05-040.8 https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly-en.html2026-05-030.8 https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly.html2026-05-030.8 https://drugnews.com.tw/articles/2026-05-02-sun-pharma-organon-acquisition-en.html2026-05-020.8 https://drugnews.com.tw/articles/2026-05-02-sun-pharma-organon-acquisition.html2026-05-020.8 https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse-en.html2026-05-010.8 https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse.html2026-05-010.8 https://drugnews.com.tw/articles/2026-04-30-amazon-ai-nvidia-en.html2026-04-300.8 https://drugnews.com.tw/articles/2026-04-30-amazon-ai-nvidia.html2026-04-300.8 https://drugnews.com.tw/articles/2026-04-29-dcard-261388300-en.html2026-04-290.8 https://drugnews.com.tw/articles/2026-04-29-dcard-261388300.html2026-04-290.8 https://drugnews.com.tw/articles/2026-04-28-dcard-261381952-en.html2026-04-280.8 https://drugnews.com.tw/articles/2026-04-28-dcard-261381952.html2026-04-280.8 https://drugnews.com.tw/articles/2026-04-27-car-t-en.html2026-04-270.8 https://drugnews.com.tw/articles/2026-04-27-car-t.html2026-04-270.8 https://drugnews.com.tw/articles/2026-04-26-dcard-261370593-en.html2026-04-260.8 https://drugnews.com.tw/articles/2026-04-26-dcard-261370593.html2026-04-260.8 https://drugnews.com.tw/articles/2026-04-25-biotech-5-en.html2026-04-250.8 https://drugnews.com.tw/articles/2026-04-25-biotech-5.html2026-04-250.8 https://drugnews.com.tw/articles/2026-04-24-dcard-261359193-en.html2026-04-240.8 https://drugnews.com.tw/articles/2026-04-24-dcard-261359193.html2026-04-240.8 https://drugnews.com.tw/articles/2026-04-23-dcard-261352566-en.html2026-04-230.8 https://drugnews.com.tw/articles/2026-04-23-dcard-261352566.html2026-04-230.8 https://drugnews.com.tw/articles/2026-04-22-ai-en.html2026-04-220.8 https://drugnews.com.tw/articles/2026-04-22-ai.html2026-04-220.8 https://drugnews.com.tw/articles/2026-04-21-dcard-261339270-en.html2026-04-210.8 https://drugnews.com.tw/articles/2026-04-21-dcard-261339270.html2026-04-210.8 https://drugnews.com.tw/articles/2026-04-20-dcard-261332702-en.html2026-04-200.8 https://drugnews.com.tw/articles/2026-04-20-dcard-261332702.html2026-04-200.8 https://drugnews.com.tw/articles/2026-04-19-neuralink-10-en.html2026-04-190.8 https://drugnews.com.tw/articles/2026-04-19-neuralink-10.html2026-04-190.8 https://drugnews.com.tw/articles/2026-04-18-biotech-ai-en.html2026-04-180.8 https://drugnews.com.tw/articles/2026-04-18-biotech-ai.html2026-04-180.8 https://drugnews.com.tw/articles/2026-04-17-dcard-261315054-en.html2026-04-170.8 https://drugnews.com.tw/articles/2026-04-17-dcard-261315054.html2026-04-170.8 https://drugnews.com.tw/articles/2026-04-16-2026-q2-en.html2026-04-160.8 https://drugnews.com.tw/articles/2026-04-16-2026-q2.html2026-04-160.8 https://drugnews.com.tw/articles/2026-04-15-biotech-en.html2026-04-150.8 https://drugnews.com.tw/articles/2026-04-15-biotech.html2026-04-150.8 https://drugnews.com.tw/articles/2026-04-14-dcard-261295358-en.html2026-04-140.8 https://drugnews.com.tw/articles/2026-04-14-dcard-261295358.html2026-04-140.8 https://drugnews.com.tw/articles/2026-04-13-78-en.html2026-04-130.8 https://drugnews.com.tw/articles/2026-04-13-78.html2026-04-130.8 https://drugnews.com.tw/articles/2026-04-12-dcard-261282303-en.html2026-04-120.8 https://drugnews.com.tw/articles/2026-04-12-dcard-261282303.html2026-04-120.8 https://drugnews.com.tw/articles/2026-04-11-dcard-261276232-en.html2026-04-110.8 https://drugnews.com.tw/articles/2026-04-11-dcard-261276232.html2026-04-110.8 https://drugnews.com.tw/articles/2026-04-10-dcard-261269760-en.html2026-04-100.8 https://drugnews.com.tw/articles/2026-04-10-dcard-261269760.html2026-04-100.8 https://drugnews.com.tw/articles/2026-04-09-dcard-261263509-en.html2026-04-090.8 https://drugnews.com.tw/articles/2026-04-09-dcard-261263509.html2026-04-090.8 https://drugnews.com.tw/articles/2026-04-08-abivax-14-en.html2026-04-080.8 https://drugnews.com.tw/articles/2026-04-08-abivax-14.html2026-04-080.8 https://drugnews.com.tw/articles/2026-04-07-cdc-en.html2026-04-070.8 https://drugnews.com.tw/articles/2026-04-07-cdc.html2026-04-070.8 https://drugnews.com.tw/articles/2026-04-06-420-en.html2026-04-060.8 https://drugnews.com.tw/articles/2026-04-06-420.html2026-04-060.8 https://drugnews.com.tw/articles/2026-04-05-dcard-261238352-en.html2026-04-050.8 https://drugnews.com.tw/articles/2026-04-05-dcard-261238352.html2026-04-050.8 https://drugnews.com.tw/articles/2026-04-04-dcard-261232633-en.html2026-04-040.8 https://drugnews.com.tw/articles/2026-04-04-dcard-261232633.html2026-04-040.8 https://drugnews.com.tw/articles/2026-04-03-dcard-261227197-en.html2026-04-030.8 https://drugnews.com.tw/articles/2026-04-03-dcard-261227197.html2026-04-030.8 https://drugnews.com.tw/articles/2026-04-02-dcard-261221419-en.html2026-04-020.8 https://drugnews.com.tw/articles/2026-04-02-dcard-261221419.html2026-04-020.8 https://drugnews.com.tw/articles/2026-04-01-dcard-261215001-en.html2026-04-010.8 https://drugnews.com.tw/articles/2026-04-01-dcard-261215001.html2026-04-010.8